FGP
MRNA icon

Freestone Grove Partners’s Moderna MRNA Stock Holding History

Freestone Grove Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.1K Buy
+659
New +$34.1K ﹤0.01% 872
2025
Q3 		– Sell
-14,272
Closed -$394K – 830
2025
Q2 		$394K Buy
+14,272
New +$376K ﹤0.01% 562

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Freestone Grove Partners's MRNA Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Moderna (MRNA) in Q2 2026: 659 shares worth $46.1K. The stake represents ﹤0.01% of the portfolio and ranks #872 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in MRNA as recently as Q2 2025.

Freestone Grove Partners first reported a position in MRNA in Q2 2025 and has held it in 2 quarters since. The position peaked at $394K in Q2 2025. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Freestone Grove Partners held 659 shares of Moderna worth $46.1K as of Q2 2026.
  • Moderna was a new Freestone Grove Partners position in Q2 2026.
  • Moderna made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #872 holding.
  • Freestone Grove Partners first reported a position in Moderna in Q2 2025 and has held it in 2 quarters since.
  • Freestone Grove Partners's Moderna position peaked at $394K in Q2 2025.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.